Cryo-EM structures of multiple-peptide resistance factor (MprF) from Pseudomonas aeruginosa.
Peptide resistance just got a new spotlight thanks to a fresh cryo-EM study of MprF from Pseudomonas aeruginosa. Researchers from the National Centre for Biological Sciences dug deep into how this enzyme helps bacteria adapt and survive peptide-based threats. This is the kind of structural data that could reshape how the peptide research community thinks about microbial defense.
FEBS J
by Jha S, Vinothkumar KR
“Cryo-EM structures of multiple-peptide resistance factor (MprF) from Pseudomonas aeruginosa. Jha S(1), Vinothkumar KR(1). Author information: (1)National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bengaluru, India. Aminoacylation of the lipid head group in many bacteria is carried out by bi-functional enzymes called MprF, which encode a soluble synthase domain that typically transfers lysine or alanine from a tRNA to lipid head groups. The modified lipid is subsequently translocated across the leaflets by a transmembrane domain. This modification of lipids probably evolved to adapt to the environment where the microbes reside. Here, we describe the cryo-EM structures of MprF enzyme from Pseudomonas aeruginosa, revealing a dimeric enzyme with a distinct architecture when compared with the homologous Rhizobium enzymes, and validate this arrangement with biochemical analyses. The cryo-EM maps and the models in detergent micelle and nanodisc reveal a conformational change of the terminal helix of the synthase domain, highlighting the dynamic elements in the enzyme that might facilitate catalysis. Several lipid-like densities are observed in the cryo-EM maps, which might indicate the path taken by the lipids, coupling the function of the two domains. The structures allow postulation of the binding modes of tRNA and lipid transport, and suggest that the mobile secondary structural elements in the synthase domain might play a mechanistic role in these functions. © 2026 The Author(s). The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.”
Key takeaway: MprF isn’t just a one-trick enzyme. It has a dual role—first, it modifies lipid head groups by slapping on amino acids like lysine or alanine, then it flips these modified lipids across the bacterial membrane. This two-step process isn’t just academic; it’s central to how bacteria deal with environmental challenges, including peptide-based antimicrobial agents.
Here’s what stands out from the cryo-EM data:
The Pseudomonas MprF enzyme forms a dimer with a structure distinct from its cousins in other bacteria.
The terminal helix of the synthase domain isn’t static. It shifts conformation, hinting at a dynamic mechanism that could help drive catalysis.
Lipid-like densities show up in the cryo-EM maps—giving clues about how lipids move between the enzyme’s two main domains.
For anyone researching peptide resistance, these findings open up new avenues. The clear visualization of mobile elements in MprF points to possible intervention points, or at least a better understanding of how bacteria outmaneuver peptide compounds. This is classic basic science fueling future translational work.
Want to keep up with the latest on peptide resistance and bacterial adaptation? Check the peptide research index for more foundational discoveries. The field just got a bit clearer, thanks to some sharp structural biology.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.